Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2015 | Therapeutic opportunities for lenalidomide in non-Hodgkin lymphoma

Nathan Fowler • 3 Oct 2015
iwNHL 2015
Non-Hodgkin Lymphoma Lenalidomide

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Nathan H. Fowler, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the ongoing clinical trials that are investigating the use of lenalidomide, an immunomodulatory drug, as monotherapy or in combination for the treatment of different subtypes of non-Hodgkin lymphoma.

More from Nathan Fowler

1:36
ELARA: Tisa-cel in follicular lymphoma
Nathan Fowler • 12 Dec 2021
0:39
10 year follow up of rituximab and lenalidomide in low tumor burden FL
Nathan Fowler • 12 Dec 2021
1:03
RELEVANCE: Rituximab and lenalidomide in FL
Nathan Fowler • 12 Dec 2021
3:44
ELARA: tisa-cel in R/R follicular lymphoma
Nathan Fowler • 18 Jun 2021

Related Videos

3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals